Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.89 is 20% below its 5-year average of -0.74, near the low end of its 5-year range (-1.16–-0.21).
1.66% above its 12-month average of -0.91.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.21.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 20 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.89
EARNINGS PER SHARE (EPS) AVG TTM
-0.91
EARNINGS PER SHARE (EPS) AVG 3Y
-0.79
EARNINGS PER SHARE (EPS) AVG 5Y
-0.74
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.66%
CURRENT VS 3Y AVG
-11.95%
CURRENT VS 5Y AVG
-20.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Genelux Corporation
Market Cap
$117.54M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
Market Cap
$117.61M
Earnings Per Share (EPS)
-1.08
TTM Avg
-1.62
3Y Avg
-1.56
5Y Avg
-1.43
Market Cap
$117.58M
Earnings Per Share (EPS)
-4.09
TTM Avg
-2.59
3Y Avg
-6.03
5Y Avg
-6.97
Market Cap
$119.64M
Earnings Per Share (EPS)
-1.52
TTM Avg
-3.16
3Y Avg
-3.35
5Y Avg
-6.72
Market Cap
$120.68M
Earnings Per Share (EPS)
-0.54
TTM Avg
-0.92
3Y Avg
-84.40
5Y Avg
-674.41
Market Cap
$121.37M
Earnings Per Share (EPS)
-1.65
TTM Avg
-6.80
3Y Avg
-14.48
5Y Avg
-27.17
Market Cap
$115.16M
Earnings Per Share (EPS)
-0.33
TTM Avg
-0.41
3Y Avg
-0.34
5Y Avg
-0.29
Market Cap
$121.25M
Earnings Per Share (EPS)
-0.28
TTM Avg
-1.88
3Y Avg
-2.46
5Y Avg
-1.80
Market Cap
$114.10M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.87
3Y Avg
-1.14
5Y Avg
-0.92
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $117.54M | -0.89 | -0.91 | -0.79 | -0.74 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.61M | -1.08 | -1.62 | -1.56 | -1.43 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.58M | -4.09 | -2.59 | -6.03 | -6.97 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $119.64M | -1.52 | -3.16 | -3.35 | -6.72 |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.68M | -0.54 | -0.92 | -84.40 | -674.41 |
| Cibus, Inc. (CBUS)vs › | $121.37M | -1.65 | -6.80 | -14.48 | -27.17 |
| MaxCyte, Inc. (MXCT)vs › | $115.16M | -0.33 | -0.41 | -0.34 | -0.29 |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | -0.28 | -1.88 | -2.46 | -1.80 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.10M | -0.47 | -0.87 | -1.14 | -0.92 |
| Coya Therapeutics, Inc. (COYA)vs › | $113.42M | -1.07 | -1.13 | -1.07 | -0.91 |
Trailing EPS (TTM)
$-0.89
Forward EPS (Est.)
$-0.81
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.86 |
| 2024-12-31 | -0.95 |
| 2023-12-31 | -1.16 |
| 2022-12-31 | -0.21 |
| 2021-12-31 | -0.69 |
| 2020-12-31 | -0.58 |
| 2019-12-31 | -0.49 |
